Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 501–600 of 1,049

1. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
   Chris Karlovich, Jonathan Wade Goldman, Jong‐Mu Sun, Elaina Mann, Lecia Van Dam Sequist, Krzysztof Konopa, Wei Wen, Philipp Angenendt, Leora Horn, David Robert Spigel et al. · 2016 · Clinical Cancer Research
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
   Xiaozheng Chen, Aiqin Gao, Fang Zhang, Zijiang Yang, Shuyun Wang, Yuying Fang, Juan Li, Jingnan Wang, Wenjing Shi, Linlin Wang et al. · 2021 · Theranostics
3. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations
   Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya et al. · 2013 · Cancer
4. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
   Zachary Alan Yochum, Jessica Cades, Hailun Wang, Suman Chatterjee, Brian Wesley Simons, James P. O’Brien, Susheel K. Khetarpal, Ghali Lemtiri-Chlieh, Kayla V. Myers, Eric H.‐B. Huang et al. · 2018 · Oncogene
5. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
   Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
6. Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
   Zhang, Yaxiong, Sheng, Jin, Kang, Shiyang, Fang, Wenfeng, Yan, Yue, Hu, Zhihuang, Hong, Shaodong, Wu, Xuan, Qin, Tao, Liang, Wenhua et al. · 2014 · PLoS ONE
7. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
   Russo, Alessandro, Franchina, Tindara, Rita Ricciardi, Giuseppina Rosaria, Picone, Antonio, Ferraro, Giuseppa, Zanghì, Mariangela, Toscano, Giuseppe, Giordano, Antonio, Adamo, Vincenzo · 2015 · Oncotarget
8. Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
   Shejuan An, Zhi Hong Chen, Jian Su, Xu‐Chao Zhang, Wen-Zhao Zhong, Jin−Ji Yang, Qing Hua Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan et al. · 2012 · PLoS ONE
9. Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
   Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, Francesca Romana Tofanetti, Annamaria Siggillino, Antonella Flacco et al. · 2011 · Journal of Thoracic Oncology
10. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
    Siow Ming Lee, Iftekhar Khan, S. Upadhyay, Conrad R. Lewanski, Stephen J. Falk, G. Skailes, Ernie Marshall, Penella J. Woll, Matthew Q F Hatton, Rohit Lal et al. · 2012 · The Lancet Oncology
11. Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer
    Fang Wei, Chien‐Chung Lin, Aron Y. Joon, Ziding Feng, Gabriel E. Troche, Maruja E. Lira, David Chia, Mao Mao, Chung‐Liang Ho, Wu‐Chou Su et al. · 2014 · American Journal of Respiratory and Critical Care Medicine
12. Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
    Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura et al. · 2017 · Cancer Research
13. Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
    Sandra Rayego‐Mateos, Raúl R. Rodrigues-Díez, José Luis Morgado‐Pascual, Floris A. Valentijn, José Manuel Valdivielso, Roel Goldschmeding, Marta Ruiz-Ortega · 2018 · Mediators of Inflammation
14. Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer
    Adi F. Gazdar · 2009 · New England Journal of Medicine
15. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
    Su, Zengliu, Dias-Santagata, Dora, Duke, MarKeesa, Hutchinson, Katherine, Lin, Ya-Lun, Borger, Darrell R., Chung, Christine H., Massion, Pierre P., Vnencak-Jones, Cindy L., Iafrate, A. John et al. · 2011 · The Journal of Molecular Diagnostics
16. The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
    Heon, Stephanie, Yeap, Beow Y., Lindeman, Neal I., Joshi, Victoria A., Butaney, Mohit, Britt, Gregory J., Costa, Daniel B., Rabin, Michael S., Jackman, David M., Johnson, Bruce E. · 2012 · Clinical Cancer Research
17. A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck
    Carol M. Lewis, Bonnie S. Glisson, Lei Feng, Fiona Wan, Ximing Tang, Ignacio Ivan Wistuba, Adel K. El‐Naggar, David I. Rosenthal, Mark Steven Chambers, Robert A. Lustig et al. · 2012 · Clinical Cancer Research
18. Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes
    Hyun-Ju Lee, Young Tae Kim, Chang Hyun Kang, Binsheng Zhao, Yongqiang Tan, Lawrence Howard Schwartz, Thorsten Persigehl, Yoon Kyung Jeon, Doo Hyun Chung · 2013 · Radiology
19. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations
    Riyaz N.H. Shah, Jason Francis Lester · 2019 · Clinical Lung Cancer
20. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
    Nahar, Rahul, Zhai, Weiwei, Zhang, Tong, Takano, Angela, Khng, Alexis J., Lee, Yin Yeng, Liu, Xingliang, Lim, Chong Hee, Koh, Tina P. T., Aung, Zaw Win et al. · 2018 · Nature Communications
21. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
    Grzegorz J. Korpanty, Donna M. Graham, Mark David Vincent, Natasha B. Leighl · 2014 · Frontiers in Oncology
22. Targeting ALK in neuroblastoma—preclinical and clinical advancements
    Erica L. Carpenter, Yaël P. Mossé · 2012 · Nature Reviews Clinical Oncology
23. Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
    Noriaki Sunaga, David S. Shames, Luc Girard, Michael Peyton, Jill E. Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira et al. · 2011 · Molecular Cancer Therapeutics
24. Genetic architecture of colorectal cancer
    Ulrike Peters, Stephanie A. Bien, Niha Zubair · 2015 · Gut
25. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS
    Angela Rose Brannon, Gowtham Jayakumaran, Monica S. Diosdado, Juber Patel, Разумова Анна Ивановна, Yu Hu, Fanli Meng, Mohammad Haque, Justyna Sadowska, Brian J. Murphy et al. · 2021 · Nature Communications
26. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
    Martin Reck, Koichi Hagiwara, Baohui Han, Sergei Tjulandin, Christian Grohé, Takashi Yokoi, Alessandro Morabito, Silvia Novello, Edurne Arriola, Olivier Molinier et al. · 2016 · Journal of Thoracic Oncology
27. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
    Jin Hyun Park, Yu Jung Kim, Jeong‐Ok Lee, Keun‐Wook Lee, Jee Hyun Kim, Soo‐Mee Bang, Jin-Haeng Chung, Kim Js, Jong Seok Lee · 2011 · Lung Cancer
28. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
    Davina Gillian Gale, Andrew R. J. Lawson, Karen Howarth, Mikidache Madi, Bradley Durham, Sarah Smalley, John D. Calaway, Shannon Blais, Greg Jones, James Clark et al. · 2018 · PLoS ONE
29. Nanotechnology in the diagnosis and treatment of lung cancer
    Alexander M. Cryer, Andrew J. Thorley · 2019 · Pharmacology & Therapeutics
30. An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
    Natasha B. Leighl, Sharon Nirmalakumar, Doreen Anuli Ezeife, Bishal Gyawali · 2021 · American Society of Clinical Oncology Educational Book
31. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer
    Pei N. Ding, Sarah J. Lord, Val Gebski, Matthew Jon Links, Victoria Bray, Richard J. Gralla, James Chih‐Hsin Yang, Chee Khoon Lee · 2016 · Journal of Thoracic Oncology
32. Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation
    Jin‐Ji Yang, Xu‐Chao Zhang, Jian Su, Chong‐Rui Xu, Qing Hua Zhou, Hong-Xia Tian, Zhi Xie, Hua-Jun Chen, Yi-Sheng Huang, Ben‐Yuan Jiang et al. · 2014 · Clinical Cancer Research
33. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
    Umberto Malapelle, Rafael Sirera, Eloisa Jantus Lewintre, Pablo Reclusa, Silvia Calabuig Fariñas, Ana Blasco, Pasquale Pisapia, Christian Diego Rolfo, Carlos Camps · 2017 · Expert Review of Molecular Diagnostics
34. Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
    Thomas Zander, Matthias Scheffler, Lucia Nogová, Carsten Kobe, Walburga Engel-Riedel, Martin Hellmich, Irini Papachristou, Karin Toepelt, Andreas Draube, Lukas Carl Heukamp et al. · 2011 · Journal of Clinical Oncology
35. A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer
    Sarah B. Goldberg, Jeffrey G. Supko, Joel W. Neal, Alona Muzikansky, Subba Rao Digumarthy, Panos Fidias, Jennifer S. Temel, Rebecca Suk Heist, Alice Tsang Shaw, Patricia McCarthy et al. · 2012 · Journal of Thoracic Oncology
36. MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
    Mengru Cao, Masahiro Seike, Chie Soeno, Hideaki Mizutani, Kazuhiro Kitamura, Yuji Minegishi, Rintaro Noro, Akinobu Yoshimura, Li Cai, Akihiko Gemma · 2012 · International Journal of Oncology
37. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer
    Hye Ryun Kim, Dae Joon Kim, Dae Ryong Kang, Jin Gu Lee, Sun Min Lim, Chang Young Lee, Sun Young Rha, Mi Kyung Bae, Young Joo Lee, Se Hoon Kim et al. · 2012 · Journal of Clinical Oncology
38. EGFR TKI combination with immunotherapy in non-small cell lung cancer
    Myung‐Ju Ahn, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park · 2017 · Expert Opinion on Drug Safety
39. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement
    Shuangshuang Li, Min Jiang, Lu Wang, Shuwen Yu · 2020 · Biomedicine & Pharmacotherapy
40. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
    Yixiang Gu, Ruifeng Yang, Yang Zhang, Miaomiao Guo, Kyle Takehiro, Ming Zhan, Linhua Yang, Hui Wang · 2025 · Molecular Biomedicine
41. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
    Rachel M. A. Linger, Amy K. Keating, Henry Shelton Earp, Douglas K. Graham · 2010 · Expert Opinion on Therapeutic Targets
42. Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
    Rachel G. Liao, Joonil Jung, Jeremy H. Tchaicha, Matthew D. Wilkerson, Andrey Sivachenko, Ellen M. Beauchamp, Qingsong Liu, Trevor J. Pugh, Chandra Sekhar Pedamallu, David Neil Hayes et al. · 2013 · Cancer Research
43. The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
    Saroj Niraula, Boštjan Šeruga, Alberto Ocaña, Tiffany Shao, Robyn Goldstein, Ian F. Tannock, Eitan Amir · 2012 · Journal of Clinical Oncology
44. Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
    Myung‐Ju Ahn, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila A. Bazhenova, Lecia Van Dam Sequist, Toyoaki Hida, James Chih‐Hsin Yang, Suresh S. Ramalingam, Tetsuya Mitsudomi, Pasi Antero Janne et al. · 2018 · Cancer
45. Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
    Faye M. Johnson, Benjamin Nebiyou Bekele, Lei Feng, Ignacio Ivan Wistuba, Xi Tang, Hai Thanh Tran, Jeremy J. Erasmus, Li-Ling Hwang, Naoko Takebe, George R. Blumenschein et al. · 2010 · Journal of Clinical Oncology
46. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung
    Sehui Kim, Jaemoon Koh, Moon‐Young Kim, Dohee Kwon, Heounjeong Go, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung · 2016 · Human Pathology
47. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
    Lucy R. Yates, Joan Seoane, Christophe Le Tourneau, Lillian L. Siu, Richard Marais, Stefan Michiels, Jean‐Charles Soria, Peter J. Campbell, Nicola Normanno, Aldo Scarpa et al. · 2017 · Annals of Oncology
48. Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)
    Rieke Frank, Matthias Scheffler, Sabine Merkelbach‐Bruse, Michaela A. Ihle, Anna Kron, Michael Rauer, Frank Ueckeroth, Katharina König, Sebastian Yves Friedrich Michels, Rieke Nila Fischer et al. · 2018 · Clinical Cancer Research
49. EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies
    Jia, Yijun, Li, Xuefei, Jiang, Tao, Zhao, Sha, Zhao, Chao, Zhang, Limin, Liu, Xiaozhen, Shi, Jinpeng, Qiao, Meng, Luo, Jiawei et al. · 2019 · International Journal of Cancer
50. Association of <i>KRAS</i> and <i>EGFR</i> mutations with survival in patients with advanced lung adenocarcinomas
    Johnson, Melissa L., Sima, Camelia S., Chaft, Jamie, Paik, Paul K., Pao, William, Kris, Mark G., Ladanyi, Marc, Riely, Gregory J. · 2013 · Cancer
51. The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
    Liza Cosca Villaruz, Mark A. Socinski · 2013 · Clinical Cancer Research
52. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers
    Lino Möhrmann, Helen J. Huang, David S. Hong, Apostolia Maria Tsimberidou, Siqing Fu, Sarina Anne Piha-Paul, Vivek Subbiah, Daniel D. Karp, Aung Naing, Anne Krug et al. · 2017 · Clinical Cancer Research
53. <i>EGFR</i> Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
    Chen, Zhi-Yong, Zhong, Wen-Zhao, Zhang, Xu-Chao, Su, Jian, Yang, Xue-Ning, Chen, Zhi-Hong, Yang, Jin-Ji, Zhou, Qing, Yan, Hong-Hong, An, She-Juan et al. · 2012 · The Oncologist
54. Chronotherapy and the molecular clock: Clinical implications in oncology☆
    Pasquale F. Innominato, Françis Lévi, Georg A. Bjarnason · 2010 · Advanced Drug Delivery Reviews
55. Realities and Expectations of Pharmacogenomics and Personalized Medicine: Impact of Translating Genetic Knowledge into Clinical Practice
    Alessio Squassina, Mirko Manchia, Vangelis G. Manolopoulos, Mehmet Artaç, Christina Lappa-Manakou, Sophia Karkabouna, Konstantinos A. Mitropoulos, Maria Del Zompo, George P. Patrinos · 2010 · Pharmacogenomics
56. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
    Gerd Goeckenjan, H. Sitter, Michael Thomas, Detlev Branscheid, Michael P. Flentje, Frank Griesinger, N. Niederle, Martin Stuschke, Torsten Gerriet Blum, KM Deppermann et al. · 2010 · Pneumologie
57. <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
    Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro et al. · 2015 · Oncotarget
58. Targeted therapies for non-small cell lung cancer
    Wolfram C. M. Dempke, Tamás Sütö, Martin Reck · 2009 · Lung Cancer
59. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
    Jin‐Ji Yang, Hua‐Jun Chen, Hong‐Hong Yan, Xu‐Chao Zhang, Qing Hua Zhou, Jian Su, Zhen Wang, Chong‐Rui Xu, Yi-Sheng Huang, Bin-Chao Wang et al. · 2012 · Lung Cancer
60. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators
    Murry W. Wynes, Lynette Marie Sholl, Manfred Dietel, Ed M. D. Schuuring, Ming‐Sound Tsao, Yasushi Yatabe, Raymond R. Tubbs, Fred R. Hirsch · 2014 · Journal of Thoracic Oncology
61. Simulating biologically plausible complex survival data
    Michael J. Crowther, Paul C. Lambert · 2013 · Statistics in Medicine
62. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
    Crispin T. Hiley, John P. C. Le Quesne, George Santis, Rowena Sharpe, David González de Castro, Gary Middleton, Charles Swanton · 2016 · The Lancet
63. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
    Patel, Harun, Pawara, Rahul, Ansari, Azim, Surana, Sanjay · 2017 · European Journal of Medicinal Chemistry
64. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
    Sang Yun Ha, So‐Jung Choi, Jong Ho Cho, Hye Joo Choi, Jinseon Lee, Kyungsoo Jung, Darryl Luke Irwin, Xiao Liu, Maruja E. Lira, Mao Mao et al. · 2015 · Oncotarget
65. Rapid 3D Extrusion of Synthetic Tumor Microenvironments
    Joshua M. Grolman, Douglas Zhang, Andrew M. Smith, Jeffrey S. Moore, Kristopher Alan Kilian · 2015 · Advanced Materials
66. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival
    Guo Li, Bai Shu-ping, Ling Zhao, Xiao-Hong Wang · 2011 · Medical Oncology
67. Molecular histology of lung cancer: From targets to treatments
    Steven L. Wood, Maria Pernemalm, Philip A.J. Crosbie, Anthony David Whetton · 2015 · Cancer Treatment Reviews
68. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
    Jaemoon Koh, Heounjeong Go, Bhumsuk Keam, Moon‐Young Kim, Soo Jeong Nam, Tae Min Kim, Se‐Hoon Lee, Hye Sook Min, Young Tae Kim, Dong‐Wan Kim et al. · 2015 · Modern Pathology
69. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
    Jill Wykosky, Tim R. Fenton, Frank B. Furnari, Webster K. Cavenee · 2011 · 癌症：英文版
70. The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
    Pedro Nazareth Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, Gilberto De Lima Lopes Jr., Bruno Andraus Filardi, Pedro Fontes Oliveira, Giannis Mountzios, Ramon Andrade de Mello · 2016 · Immunotherapy
71. The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
    Raul Caso, Francisco Sánchez-Vega, Kay See Tan, Brooke Mastrogiacomo, Jian Hua Zhou, Gregory D. Jones, Bastien Nguyen, Nikolaus D. Schultz, James G. Connolly, Whitney S. Brandt et al. · 2020 · Journal of Thoracic Oncology
72. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
    Cortot, Alexis B., Jänne, Pasi A. · 2014 · European Respiratory Review
73. Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
    Jeong‐Ok Lee, Tae Min Kim, Se‐Hoon Lee, Dong‐Wan Kim, Soyeon Kim, Yoon‐Kyung Jeon, Doo Hyun Chung, Woo Ho Kim, Young Tae Kim, Seok-Chul Yang et al. · 2011 · Journal of Thoracic Oncology
74. Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
    Marta Salido, Lara Pijuán, Luz Maria Martinez-Aviles, Ana B. Galván, Israel Cañadas, Ana Rovira, Montserrat Zanui, Alejandro Martínez, Raquel Longarón, Francesc Gessé Solé et al. · 2010 · Journal of Thoracic Oncology
75. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    Itziar Otano, Alvaro Conrado Ucero, Jon Zugazagoitia, Luis G Paz-Ares · 2023 · Nature Reviews Clinical Oncology
76. Personalized medicine in lung cancer: what we need to know
    Tony S.K. Mok · 2011 · Nature Reviews Clinical Oncology
77. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
    Vanesa Gregorc, Silvia Novello, Chiara Lazzari, Sandro Barni, Michele Aieta, Manlio Mencoboni, Francesco Grossi, Tommaso Martino De Pas, Filippo de Marinis, Alessandra Bearz et al. · 2014 · The Lancet Oncology
78. Seipin: from human disease to molecular mechanism
    Bethany R. Cartwright, Joel M. Goodman · 2012 · Journal of Lipid Research
79. Synthetic lethality-mediated precision oncology via the tumor transcriptome
    Joo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang, Sanju Sinha, Hongui Cha, Dasol Kim, Alexander V. Schperberg et al. · 2021 · Cell
80. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
    Sabina A Antoniu · 2011 · Expert Opinion on Therapeutic Targets
81. Treatment of advanced non small cell lung cancer.
    Maria Anna Bareschino, Clorinda Schettino, Antônio Rossi, Paolo Maione, Paola Claudia Sacco, Rosario Zeppa, Cesare Gridelli · 2011 · Europe PMC (PubMed Central)
82. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
    Meghan Shea, Daniel Botelho Costa, Deepa Rangachari · 2015 · Therapeutic Advances in Respiratory Disease
83. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
    Ji Yun Lee, XU Qing, Xiumin Wei, Bai Yali, Sangah Chi, So Hyeon Bak, Ho Yun Lee, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn et al. · 2016 · Oncotarget
84. A post‐genomic surprise. The molecular reinscription of race in science, law and medicine
    Duster, Troy · 2015 · The British Journal of Sociology
85. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Hongbing Liu, Ying Wu, Tangfeng Lv, Yan-wen Yao, Yongying Xiao, Dongmei Yuan, Yong Song · 2013 · PLoS ONE
86. Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of18F-FDG Uptake at PET—Association with Treatment Response and Prognosis
    Gary Cook, Mary E.R. O'Brien, Muhammad Siddique, Sugama Chicklore, Hoi Yin Loi, Bhupinder Sharma, Ravi Punwani, Paul Bassett, Vicky Goh, Sue C. Chua · 2015 · Radiology
87. A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer
    Ji‐Youn Han, Soo-Hyun Lee, Nam Jin Yoo, Lee Suk Hyung, Yoon Joo Moon, Tak Yun, Heung Tae Kim, Jin Soo Lee · 2011 · Clinical Cancer Research
88. Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
    Mauricio Burotto, Elisabet Esteve Manasanch, Julia Wilkerson, Tito Fojo · 2015 · The Oncologist
89. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
    Yamamoto, Chizuko, Basaki, Yuji, Kawahara, Akihiko, Nakashima, Kazutaka, Kage, Masayoshi, Izumi, Hiroto, Kohno, Kimitoshi, Uramoto, Hidetaka, Yasumoto, Kosei, Kuwano, Michihiko et al. · 2010 · Cancer Research
90. First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study
    Makoto Maemondo, Yuji Minegishi, Akira Inoue, Kunihiko Kobayashi, Masao Harada, Shoji Okinaga, Naoto Morikawa, Satoshi Oizumi, Tomoaki Tanaka, Hiroshi Isobe et al. · 2012 · Journal of Thoracic Oncology
91. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions
    Peters, Solange, Zimmermann, Stefan, Adjei, Alex A. · 2014 · Cancer Treatment Reviews
92. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
    Laure Sorber, Karen Zwaenepoel, Vanessa Deschoolmeester, Paul E. Van Schil, Jan P. van Meerbeeck, Filip Lardon, Christian Diego Rolfo, Patrick Pauwels · 2016 · Lung Cancer
93. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
    Tianli Zhang, Bing Wan, Yuan Zhao, Chuling Li, Hongbing Liu, Tangfeng Lv, Ping Zhan, Yong Song · 2019 · Translational Lung Cancer Research
94. Chemotherapy advances in small-cell lung cancer.
    Bryan Anthony Chan, Jermaine Ian George Coward · 2013 · Europe PMC (PubMed Central)
95. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer
    Jin Ho Paik, Chang‐Min Choi, Hyojin Kim, Se Jin Jang, Gheeyoung Choe, Dong Kwan Kim, Hwa Jung Kim, Ho-Il Yoon, Choon‐Taek Lee, Sanghoon Jheon et al. · 2011 · Lung Cancer
96. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
    Ross Andrew Soo, Sun Min Lim, Nicholas L. X. Syn, Rebecca Siew Yan Teng, Richie Soong, Tony S.K. Mok, Byoung Chul Cho · 2017 · Lung Cancer
97. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C et al. · 2017 · British Journal of Cancer
98. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
    Y. Yosaatmadja, Shevan Silva, James M. J. J. Dickson, Adam Vorn Patterson, Jeff Bruce Smaill, Jack U. Flanagan, Mark James McKeage, Christopher John Squire · 2015 · Journal of Structural Biology
99. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
    Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo‐Xun Wu, Jianye Zhang, Xuansheng Ding · 2022 · Molecular Cancer
100. Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
     A. El-Telbany, P. C. Ma · 2012 · Genes & Cancer